Literature DB >> 21841688

The management of breakthrough cancer pain.

Andrew N Davies1.   

Abstract

Breakthrough cancer pain is a heterogeneous condition, and management should involve a thorough assessment, an individualized treatment plan, and a thorough re-assessment. This article will highlight the recommendations for the management of breakthrough cancer pain from a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, and briefly review the new opioid preparations that have been developed for breakthrough pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841688     DOI: 10.12968/bjon.2011.20.13.803

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  9 in total

1.  Comment on 'What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion'.

Authors:  Raffaele Giusti; Lucilla Verna; Daniela Iacono; Agnese Vannini; Corrado Ficorella; Giampiero Porzio
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

2.  Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study.

Authors:  Marco Cascella; Anna Crispo; Gennaro Esposito; Cira Antonietta Forte; Sergio Coluccia; Giuseppe Porciello; Alfonso Amore; Sabrina Bimonte; Sebastiano Mercadante; Augusto Caraceni; Massimo Mammucari; Paolo Marchetti; Rocco Domenico Mediati; Silvia Natoli; Giuseppe Tonini; Arturo Cuomo
Journal:  Cancers (Basel)       Date:  2021-08-10       Impact factor: 6.575

Review 3.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

4.  Single-dose fentanyl sublingual spray for breakthrough cancer pain.

Authors:  Donald R Taylor
Journal:  Clin Pharmacol       Date:  2013-07-24

5.  Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.

Authors:  J Boceta; A De la Torre; D Samper; M Farto; R Sánchez-de la Rosa
Journal:  Clin Transl Oncol       Date:  2016-11       Impact factor: 3.405

6.  Breakthrough cancer pain and rational drug use.

Authors:  Juan Manuel Núñez Olarte
Journal:  Support Care Cancer       Date:  2017-02-18       Impact factor: 3.603

7.  Light-Induced Activation of a Specific Type-5 Metabotropic Glutamate Receptor Antagonist in the Ventrobasal Thalamus Causes Analgesia in a Mouse Model of Breakthrough Cancer Pain.

Authors:  Serena Notartomaso; Nico Antenucci; Francesca Liberatore; Giada Mascio; Stefano Vito Boccadamo Pompili; Joan Font; Mariarosaria Scioli; Livio Luongo; Antonietta Arcella; Roberto Gradini; Amadeu Llebaria; Ferdinando Nicoletti
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

8.  Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.

Authors:  Masoud Hashemi; Alireza Zali; Ebrahim Golmakani; Mohammad Hossein Delshad; Mahdi Shadnoush; Mohammad-Esmaeil Akbari
Journal:  Daru       Date:  2021-01-21       Impact factor: 3.117

9.  Breakthrough cancer pain - still a challenge.

Authors:  Cesar Margarit; Joaquim Juliá; Rafael López; Antonio Anton; Yolanda Escobar; Ana Casas; Juan Jesús Cruz; Rafael Galvez; Ana Mañas; Francisco Zaragozá
Journal:  J Pain Res       Date:  2012-11-19       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.